Effect of 25-hydroxycholecalciferol on calcium absorption in chronic renal disease  by Rutherford, W. Ernest et al.
Kidney International, Vol. 8, (1975). p. 320—324
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Effect of 25-hydroxycholecalciferol on calcium absorption in
chronic renal disease. Calcium absorption was measured in eight
uremic patients before and after eight days of treatment with 100 or
500 ig of 25-hydroxycholecalciferol (25(OH)D,) per day. Fraction-
al calcium absorption was estimated by administering 47Ca i.v. and
orally on separate days and counting forearm radioactivity four
hours later. Calcium absorption in four patients with residual renal
function rose from 16.3 2.5 to 40.8 5.5% after treatment. In or-
der to determine if the increased calcium absorption was mediated
by an increase in the production of 1,25-dihydroxycholecalciferol
(I ,25(OH)2D3) by virtue of increased substrate delivery to the 25-hy-
droxycholecalciferol-l-hydroxylase system present in the residual
renal tissue, identical studies were performed in four anephric
patients. Calcium absorption in these patients averaged 15.7 2.2%
during the control period and rose to 46.0 11.1% after treatment.
Increments in serum calcium after treatment were similar in both
groups of patients; the mean concentration rose from 9.6 0.3 to
11.0 0.6 mg/l00 ml. The results indicate that 25(OH)D3 can im-
prove calcium absorption in the absence of renal tissue suggesting
that its conversion to l,25(OH),D, may not be necessary for its ef-
fect on the gastrointestinal tract in the uremic patient.
Effet dii 25-bydroxycholécalciferol stir l'absorption dii calcium an
cours de t'unsuflIsance rdnale chronique. L.'absorption de calcium a
été mesurée chez huit malades urdmiques avant et aprs huit jours
de traitement par 100 ou 500 g de 25(OH)D3 par jour.
L'absorption fractionnelle du calcium a étd évaluée par
l'administration de 47Ca, intraveineuse et orale, a des jours
différents, et par comptage de l'activité de l'avant-bras quatre
heures apres. L'absorption du calcium chez quatre malades ayant
une fonction rénale résiduelle augmente de 16,3 2,5 a 40,8 5,5%
aprés traitement. Des etudes semblables ont CtC rCalisCes chez
quatre malades anéphriques de façon a apprécier Ic rdle Cventuel,
dans l'augmentation de l'absorption intestinale, d'une augmentation
de Ia production de l,25(OH)2D, due a l'augmentation de l'apport
de substrat a Ia 25-hydroxycholécalciferol- I -hydroxylase du tissu
renal. L'absorption du calcium chez ces malades est en moyenne de
15,7 2,2% pendant Ia pdriode contrôle et augmente après traite-
rnent a 46,0 11,1%. Les augmentations du calcium sériques sont
semblables dans les deux groupes de malades, Ia concentration
moyenne passe de 9,6 3 a 11,0 0,6 mg/ 100 ml. Les résultats in-
diquent que 25(OH)D, peut amCliorer l'absorption du calcium en
l'absence de tissu renal cc qui suggère que sa conversion en
I ,25(OH)2D peut ne pas &re nécessaire a son action sur le tractus
gastro-intestinal du malade urémique.
Calcium malabsorption, hypocalcemia, secondary
hyperparathyroidism and renal osteodystrophy are
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consequences of renal insufficiency [1—6] which appear
to be related, at least in part, to an alteration(s) in the
metabolism of vitamin D [1, 4, 6]. Vitamin D, per Se,
has relatively low physiologic activity and must first
be metabolized to 25-hydroxycholecalciferol,
25(O1-1)D3, by a liver microsomal enzyme system
which in mammals appears to be product inhibitable
[7—101. This inhibition may account for the fact that
the circulating concentrations of 25(OH)D3 in serum
are maintained in the range of 20 to 30 ng/ml in nor-
mal subjects and in uremic patients as well [ii]. Under
the appropriate conditions, 25(OH)D3 may undergo
further hydroxylation to 1 ,25-dihydroxycholecaliferol,
l,25(OH)2D3 [12—14]. The enzyme responsible for this
process, 25-hydroxycholecalciferol- 1 -hydroxylase, is
present exclusively in the mitochondria of the renal
cortex 115]. l,25(OH)2D3 is much more potent than
25(OH)D3 in stimulating calcium absorption and
mobilizing calcium from bone [16—181, and it is now
generally accepted that calcium malabsorption in ure-
mia is the result of insufficient conversion of
25(OH)D3 to l,25(OH)2D3. Moreover, recent studies
by Brickman, Cobum and Norman [19] have clearly
demonstrated that the administration of small
amounts of l,25(OH)2D3 to uremic patients reverses
the malabsorption of calcium and increases serum cal-
cium concentration in a relatively short period of time.
Previous studies from this laboratory demonstrated
that calcium absorption could be normalized in ure-
mic dogs by the oral administration of 25(OH)D3 [20].
This observation was of great practical interest be-
cause 25(OH)D3, unlike l,25(OH)2D3, is relatively in-
expensive and is available experimentally in large
quantities. The effect of 25(OH)D3 on calcium absorp-
tion was also of considerable theoretical interest be-
cause calcium absorption has been found to be en-
hanced by compounds which, in addition to possessing
a basic vitamin D—like structure, also generally con-
tain a hydroxyl group in the C-i position [21, 22).
25(O1-1)D3 may have normalized calcium absorp-
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tion in our uremic dogs by virtue of the fact that its
oral administration effectively bypassed the 25-hy-
droxylase system in the liver, and permitted the attain-
ment of circulating concentrations of 25(OH)D3 in ex-
cess of those which normally occur. At this higher
concentration the metabolite may be able to stimulate
calcium absorption directly or, alternatively, may per-
mit increased production of l,25(OH)2D3 or other me-
tabolites by virtue of increased delivery of 25(OH)D3
to the 1-hydroxylase system in the remaining renal
mass.
With this background in mind, the present study
was undertaken to measure calcium absorption in ure-
mic patients with residual renal function and in aneph-
nc patients before and after eight days of treatment
with 25(OH)D3.
Methods
Eight patients with chronic renal disease were ad-
mitted to the Clinical Research Center at Washington
University and fed a constant diet containing 800 mg
of calcium and 400 mg of phosphorus. Four of these
eight patients were anephric. Surgical removal of the
kidneys in these patients had been necessary to control
hypertension. Aluminum carbonate gel was adminis-
tered in a dose of 20 to 30 ml three to four times daily
to maintain the serum phosphorus concentration with-
in normal limits. An equilibration period of 10 to 14
days on this diet preceded the control calcium absorp-
tion measurements. Following this determination,
25(OH)D3 was given orally in a dose of either 500 or
100 sg daily for eight days and calcium absorption
was measured again.
Calcium absorption was estimated by a previously
described modification [23] of the method of Curtis,
Fellows and Rich [24]. The measurements were per-
formed as follows: 47Ca was given by constant i.v. in-
fusion over 90 mm and the usual breakfast containing
200 mg of calcium was given at the start of the in-
fusion. Forearm radioactivity was counted in a volume
counter (Armac) prior to the administration of isotope
and four hours later. Two days later 10 jzCi of 47Ca
was given orally with the same meal and forearm ra-
dioactivity was counted four hours later. Appropriate
counting was performed in order to correct for the ra-
dioactivity which remained from the previously ad-
ministered 47Ca. The absorption at 4 hr rather than 24
hr was measured as described by Pak et al [25]. Cal-
cium absorption is expressed as a percent of the orally
administered load. Creatinine clearance and serum
calcium and phosphorus concentrations were mea-
sured by methods previously described [26].
Results
Measurements of calcium absorption demonstrated
a marked difference between normal subjects and
patients with chronic renal disease. Figure 1 illustrates
the results obtained in a group of 5 normal volunteers
and 11 uremic patients with a mean glomerular filtra-
tion rate of 13.6 3.2 mI/mm. Mean calcium absorp-
tion was 44.4 3.5% in the normal subjects while the
uremic patients absorbed 18.6 3.4% of the orally ad-
ministered load.
The results of six studies in four patients with a
mean creatinine clearance of 2.4 1.1 ml/min on two
different dosage schedules of 25(OH)D3 are shown in
Fig. 2. An interval of approximately two months sepa-
rated the studies in the patients who received two dif-
ferent doses. Calcium absorption during the control
period averaged 16.3 2.5% and rose to 40.8 5.5%
after treatment with 25(OH)D3, thus confirming in
patients our findings in uremic dogs that 25(OH)D3 ef-
fectively increases calcium absorption in chronic renal
disease in a relatively short period of time. The small-
er dose (100 Mg) also was equally effective.
In order to determine if the improvement in calcium
absorption following the administration of 25(OH)D3
was mediated by its renal conversion to 1,25(OH)D3,
identical studies were performed in four anephric
patients. All four received 500 sg of 25(OH)D3 daily
for a period of eight days. Figure 3 shows the results of
this study.
Calcium absorption during the control period aver-
aged 15.7 2.2%; it increased to 46.0 11.1% after
the administration of 25(OH)D3. Calcium absorption
increased in all, but was highly variable from patient
to patient.
Normal Uremic
(N—5) (N=11)
Fig. 1. Calcium absorption in normal and uremic patients. Mean re-
sults and SEM for 5 normal volunteers and ii patients with chronic
renal disease.
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Fig. 2. Calcium absorption in four patients with chronic renal dis-
ease before and after eight days of treatment with 25(OH)D3. The
values for patients who received 500 pg daily are represented by
dark circles and connected by solid lines (.—.); those receiving 100
Lg daily are represented by open squares and connected by inter-
rupted lines (U- . -U).The numbers at thebottom of the figure rep-
resent the mean values and SEM for calcium absorption in six studies
performed before and after treatment.
Figure 4 depicts the changes in serum calcium con-
centration before and after eight days of treatment
with 500 Mg daily of 25(OH)D3 for eight patients with
far advanced chronic renal disease (four were aneph-
nc). The increment in serum calcium concentration af-
ter treatment with 25(OH)D3 was similar in both
groups of patients, and for all eight patients, serum
calcium concentration rose from a mean of 9.6 0.3
to 11.0 0.6 mg/lOO ml, an increase which is statisti-
cally significant at the level ofF < 0.005.
Discussion
Calcium absorption in uremic patients is relatively
unaffected by vitamin D administration except when
given in high doses. Presumably, these high doses are
required to overcome the feedback inhibition of the
25-hydroxylase system [27]. Pertinent to this is the
fact that previous studies in this laboratory under con-
ditions virtually identical to those in the present study
failed to demonstrate any significant increase in cal-
cium absorption in uremic patients given 5 mg of vita-
min D daily for eight days [23]. The administration of
25(OH)D3 bypasses the 25-hydroxylase system and
permits the attainment of high circulating concentra-
tions [27]. Evidence accumulated to date suggests that
calcium malabsorption in uremia is the result of in-
sufficient production of l,25(OH)2D3 [28, 29]. How-
ever, the administration of 25(OH)D3 in the dosage
schedule employed resulted in an increase in calcium
absorption even in the absence of renal tissue and pre-
sumably, therefore, in the absence of the 25-hydroxy-
cholecalciferol- 1 -hydroxylase system. This suggests
that high circulating concentrations of 25(OH)D3 may
be sufficient to stimulate calcium absorption without
prior conversion to l,25(OH)2D3. This conclusion is
supported by the recent observation that l,25(OH)2D3
was not detectable in the serum of anephric patients
following the administration of radiolabeled
25(OH)D3 [30] and suggests that l,25(OH)2D3 cannot
be synthesized extrarenally. The possibility of extra-
renal conversion of 25(OH)D3 to another or other
compounds capable of stimulating calcium absorption
is obviously not excluded by this study. Extrarenal
production of a compound more polar than
l,25(OH)2D3 has been found [30]. This compound co-
migrated with authentic 1 ,24,25(OH )3D3, a compound
which has been shown to be capable of stimulating cal-
cium absorption. This polar compound was, however,
probably not l,24,25(OH)3D3 since an enzyme system
capable of 1 -hydroxylation has been found exclusively
in renal tissue in mammals; and this compound was
found to be considerably less sensitive to penodate
oxidation than 1 ,24,25(OH)3D3 [30].
An apparent direct effect of 25(OH)D3 is not with-
out precedence since there is evidence that this com-
pound may act directly on bone [31—331. It is, how-
ever, clear from this study that renal tissue is not
required for 25(OH)D3 to affect an increase in calcium
absorption and to increase the serum calcium concen-
tration in uremic patients; and the possibility exists
that this compound may stimulate calcium absorption
directly.
Control 25 (OH) D3
500 pg/day
Fig. 3. Calcium absorption in four anephric patients before and after
eight days of treatment with 25(OH)D , 500 pg daily.
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Urernic Patients
Anephric Patients
Control 25 (OH) D3
500 Mg/day
Fig. 4. Serum calcium for a group offour uremic patients with resid-
ual renal function (.—.), and four anephric patients (A—A) before
and after treatment with 25(OH)D3, 500 g daily for eight days.
The serum calcium concentration increased in most
of the patients; however, the increment was indepen-
dent of renal mass and was not proportional to the in-
crease in calcium absorption. This suggests that bone
mineral mobilization may have contributed to the in-
crease in serum calcium concentration. It is possible
that the degree and predominant form of renal os-
teodystrophy, the circulating concentrations of para-
thyroid hormone as well as other factors, may be im-
portant determinants affecting the degree of bone
mineral mobilization and thereby affecting the serum
calcium concentration independent of the increase in
intestinal calcium absorption. Additional studies must
be, conducted in order to further delineate the factor(s)
responsible for the variable rise in serum calcium con-
centration. It should be emphasized that four patients
developed severe hypercalcemia (Fig. 4) after only
eight days of treatment, and therefore 500 ,ig/day of
25 (OH)D3 appears to be an excessive dose. Further-
more, since all of the factors responsible for the in-
creased calcium concentration are unknown, all
patients receiving this drug must be kept under strict
medical control and serum calcium concentration
must be monitored frequently. We have safely admin-
istered smaller doses (50 to 100 Mg/day) of 25(OH)D3
to uremic patients on a long-term basis (vide infra).
Observations in this laboratory and the work of oth-
ers suggest that 25(OH)D3 may also be beneficial in
the treatment of secondary hyperparathyroidism and
renal osteodystrophy. The nature of this study did not
allow us to gain useful information regarding changes
in parathyroid hormone concentrations in blood or
correction of osteomalacia. However, findings of long-
term studies in uremic dogs receiving 25(OH)D3 in-
dicate a complete prevention of secondary hyper-
parathyroidism in these animals [34J. Other investiga-
tors [35, 36] demonstrated that 25(OH)D3 was active
on bone of uremic patients. We also have found (Tei-
telbaum S, Kopelman R, Hruska K, Rutherford WE,
Slatopolsky E: Unpublished observations) improve-
ment in both the osteitis fibrosa and osteomalacia in
patients with advanced renal failure.
The present study indicates that 25(OH)D3 may be
a practical therapeutic adjunct in the treatment of cal-
cium malabsorption in uremic patients even in the ab-
sence of the 1 -hydroxylase system. The ultimate utility
of 25(OH)D3 as well as that of other metabolites and/
or analogues of vitamin D will, however, depend on
the economy, ease and safety with which they may be
employed to affect overall homeostatic calcium bal-
ance.
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